DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Finn RS, Kang YK, Mulcahy M , et al.
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Clin Cancer Res 2012;
18 (7) 2090-2098
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.